Eton wins FDA nod for rare disorder therapy Desmoda
Source: SeekingAlpha
2026-02-25 14:20:20 ET
More on Eton Pharmaceuticals
- Eton Pharmaceuticals: An Undervalued Small Cap With High Growth
- Seeking Alpha’s Quant Rating on Eton Pharmaceuticals
- Historical earnings data for Eton Pharmaceuticals
- Financial information for Eton Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Eton wins FDA nod for rare disorder therapy Desmoda
Eton Pharmaceutcials Inc.
NASDAQ: ETON
ETON Trading
0.97% G/L:
$18.69 Last:
83,953 Volume:
$19.08 Open:
ETON Latest News
March 03, 2026 04:30:00 pm
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 02, 2026 07:27:44 am
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
February 25, 2026 01:47:00 pm
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA(TM) (desmopressin acetate) Oral Solution
February 20, 2026 06:50:00 am
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
ETON Stock Data
$408,699,233
22,518,684
14.05%
24
N/A
Pharmaceuticals
Healthcare
US
Deer Park
